Sprague-Dawley (CD) rats were injected intravenously with ethylnitrosourea at a dose of 20 mg/kg on day 20 of gestation. This exposure resulted in early neoplastic proliferation or development of a neurinoma of the trigeminal nerve in 58% of the offspring at 90 days of age. Implantation of osmotic microinfusion pumps containing 2.5s nerve growth factor prior to ethylnitrosourea administration significantly reduced the incidence of early neoplastic proliferation. Postnatal implantation of microinfusion pumps containing 2.5s nerve growth factor also resulted in a significant but less pronounced reduction of early neoplastic proliferation. Immunoglobulin G directed against nerve growth factor (anti-nerve growth factor) did not influence the incidence of early neoplastic proliferation when administered via microinfusion pumps implanted on day 15 postnatally. These findings suggest that nerve growth factor has a protective effect on the developing nervous system against ethylnitrosourea-induced carcinogenesis.
Resorptive nitrosourea derivatives have been used to induce neurogenic tumors in several species of animals.I6 Rats are highly susceptible to development of neurogenic tumors after transplacental administration of ethylnitrosourea late in gestation. A single exposure of pregnant rats to 50 mg/kg of ethylnitrosourea on day 20 of gestation resulted in tumors of the nervous system in 100% of the off~pring.'~ Experiments on the sequential development of these lesions indicated that the trigeminal nerve was one of the earliest and most consistently involved Sequential evaluations of the morphology, biochemistry, and transplantability of trigeminal nerves from ethylnitrosourea-exposed rats from one day to six months of age2' revealed that histologic differences were present when comparing nerves of control and ethylnitrosourea-exposed rats by 20 days of age, in that 50% of nerves from the treated rats had hypercellularity, hyperchromatism, and increased numbers of mitotic figures. These changes occurred in the preganglionic segment, usually at or near the central nervous systemperipheral nervous system junction, and were accompanied by a progressive increase in N-acetyl-p-glucosaminidase and /3-glucuronidase activity to levels that were previously demonstrated in grossly visible neural t~r n o r s .~ Subcutaneous transplantation of nerves ex-posed to ethylnitrosourea into one-day-old syngeneic rats resulted in formation of neurinomas at the implantation site, while no tumors formed from transplanted nerves of controls. Based on these results, it was concluded that the morphologic changes seen represented an early neoplastic proliferation rather than a transient hyperplastic or preneoplastic tissue reaction to the carcinogen. By 63 days of age, over 70% of the trigeminal nerves examined from ethylnitrosourea-exposed rats contained early neoplastic proliferation. Surprisingly, when the peak development of neurinomas would be expected at 182 days, only 30% of the nerves contained grossly visible neurinomas. It was not determined why relatively few of the nerves with early neoplastic proliferation progressed to visible tumors. The question remains as to what host factors influence tumor cell proliferation, regression, or both. Because immunologic mechanisms do not appear to influence neurogenic tumor f~rmation,~. 23 other host factors need to be evaluated.
From the general investigations of the influence that peripheral end organs have on their associated nerve centers came the discovery of nerve growth face induction of differentiation and maturation of various in vitro and in vivo neuroectodermal tumors by nerve growth factor is well docu-tor.% 10, [18] [19] [20] 22, 30, 32 Th 61 mented.2. 5.8.25.36.37 p revious reports have suggested that treatment with nerve growth factor is associated with a reduction in the numbers of neurogenic tumors, including trigeminal neurinomas, that are induced by ethylnitrosourea in mice36 and rats3' Treatment of rats bearing implanted cells of an anaplastic glioma clone with nerve growth factor led to a decreased tumor growth rate and increased survival time. 33 In a recent study from our l a b~r a t o r y ,~~ it was observed that treatment of Fischer rats with nerve growth factor either postnatally following optimal dose ethylnitrosourea administration or transplacentally prior to optimal dose ethylnitrosourea administration appeared to result in a reduction of early neoplastic proliferation or neurinomas of trigeminal nerves at 90 days of age. The present experiment was designed to test the effect of nerve growth factor and anti-nerve growth factor, administered by slow infusion osmotic pumps, upon the development of early neoplastic proliferation of trigeminal nerves in Sprague-Dawley rats exposed transplacentally to ethylnitrosourea.
Materials and Methods
Nerve growth factor (7s) and its biologically active psubunit were isolated and purified from the submaxillary glands of adult male Swiss Webster mice.3' Biological activity was evaluated by bioassay and purity by isoelectric focusing on polyacrylamide gels." Purified rabbit immunoglobulin G directed against p-nerve growth factor (anti-nerve growth factor) was ~repared,~' and nerve growth factor (2.5s) was isolated' by previously described procedures.
Crystalline ethylnitrosourea was dissolved in saline:citratephosphate buffer (14:l; pH 4.2) shortly before use at a concentration of 10 mg/ml. Pregnant Sprague-Dawley (CD) rats (Charles River Laboratories, Wilmington, Mass.) were separated into four groups. On day 20 of gestation all rats were given a single intravenous injection of ethylnitrosourea at a dose of 20 mg/kg of body weight via the lateral tail vein. This dose was chosen because it had been shown previously to be the lowest single dose producing 100% neurogenic tumors in rats following transplacental exposure?'
Group I: This group received no further treatment.
Group ZI: On day 14 of gestation (prior to ethylnitrosourea administration), an osmotic microinfusion pump (Alzet model 2001, mean pumping rate 1.05 &hour; Alza, Palo Alto, Calif.) containing a mean fill quantity of 0.2 mg 2.5s nerve growth factor in 200 pl physiologic saline was implanted subcutaneously in the dorsal scapular region of each rat. Subsequent investigations have demonstrated that nerve growth factor retrieved from microinfusion pumps after implantation for one week retained biologic activity as determined by promotion of neurite outgrowth in pheochromocytoma clone (PC,,) cells (Vinores, S.A., unpublished observations). The surgical site was closed by interrupted silk (0000) sutures. At this capacity and diffusion rate the total amount of nerve growth factor was delivered in approximately seven days. An equal number of rats received similar implants containing only physiologic saline to serve as sham-operated controls (table I, group HA). Group ZZk On day 15 postpartum, each offspring from this group received a subcutaneously implanted microinfusion pump which contained a mean fill quantity of 0.04 mg nerve growth factor in 200 pl physiologic saline.
Group ZV: A microinfusion pump which contained antinerve growth factor (mean fill volume of 0.23 ml, initial concentration 20 times that found in the serum of immunized rabbit^,^' diluted 1 :3 with physiologic saline) was implanted on day 15 postpartum in each offspring from this group.
All offspring were killed with diethyl ether at 90 days of age and their trigeminal nerves were dissected for histologic evaluation. The preganglionic end of the nerve, including the central nervous system-peripheral nervous system junction and a small portion of the pons, was removed from the brain. The postganglionic end of the nerve was severed midway between the gasserian ganglion and the point of exit of the nerve from the skull. After fixation in 10% formalin for seven days, specimens were embedded longitudinally in parafin and serially cut at 6 pm, then stained with hematoxylin and eosin (HE). Slides were coded so that treatment and group were not known by the examiner. Sections of nerves were evaluated for early neoplastic proliferation or neurinoma formation. Criteria for early neoplastic proliferation included hypercellularity, hyperchromatism, increased numbers of mitotic figures, and loss of cellular Criteria for l a 2a l b 2b Fig. la, b: Trigeminal nerve from 90-day-old ethylnitrosourea-exposed rat. Low (0.) and high (b.) magnification of nerve with marked hypercellularity and lack of cellular organization. Central nervous system-peripheral nervous system junction (arrows). HE. Fig. 2a, 6 : Low (0.) and high (b.) magnification of non-affected trigeminal nerve from 90-day-old rat which was ethylnitrosourea-exposed following nerve growth factor treatment. Central nervous system-peripheral nervous system junction (arrows). HE. the diagnosis of neurinoma included those changes seen with early neoplastic proliferation plus evidence of invasion and regressive changes, such as cyst formation and hemor-The incidence of early neoplastic proliferation and neurinoma for each group was determined and each experimental group (11,111, and IV) was compared with the control (group I) using the Student's t-test.
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Results
The results are summarized in table I. Eleven of 19 offspring of the rats exposed to ethylnitrosourea at a dose of 20 mg/kg on day 20 of gestation (group I) had neoplastic change in their trigeminal nerves at 90 days of age. Ten rats had early neoplastic proliferation as evidenced by hypercellularity, loss of organization, hyperchromatism, and increased mitotic index (fig la, b) as compared with unaffected trigeminal nerves (fig 2a,  b) . One rat had a neurinoma detected only by histologic evaluation. The early neoplastic proliferation always was found in the preganglionic region of the nerve, usually at or near the central nervous system-peripheral nervous system junction ( fig. la, b) . In more severely affected nerves, the neoplastic proliferation extended distally into the gasserian ganglion and disrupted the normal architecture. A few rats had perivascular infiltration of adjacent vessels leading into the brain stem.
Treatment with nerve growth factor resulted in a reduction in early neoplastic proliferation in the trigeminal nerves when administered via osmotic microinfusion pumps either transplacentally before ethylnitrosourea exposure (p < 0.025) or postnatally after ethylnitrosourea exposure (p < 0.05) (table I) . Transplacental treatment with nerve growth factor (group 11) was the most effective in that 74% of the offspring had no neoplastic change. Treatment with nerve growth factor postnatally (group 111) also resulted in an effective reduction in early neoplastic proliferation, with 72% of the rats having no detectable neoplastic change. These treatment schedules were not significantly different from each other, but both had less early neoplastic proliferation than controls. Neither of the nerve growth factor treatment groups (groups 11, 111) had microneurinomas or grossly visible neurinomas of the trigeminal nerves.
Postnatal treatment with anti-nerve growth factor did not effect the incidence of trigeminal nerve early neoplastic proliferation in ethylnitrosourea-treated rats (table I). Nine of 18 rats had early neoplastic proliferation in the trigeminal nerve. One rat from this group had a trigeminal nerve with a grossly detectable neurinoma ( fig. 3) .
The number of sham-operated offspring (ethylnitrosourea-exposed; surgical implants containing only physiologic saline) affected with early neoplastic proliferation of the trigeminal nerve was not significantly different from rats which were exposed only to ethylnitrosourea.
In all four groups, the presence of early neoplastic proliferation in the trigeminal nerves appeared to be primarily unilateral (table 11) . There was no predilection for either the left or right nerve.
Discussion
When nerve growth factor was administered to Sprague-Dawley (CD) rats via surgically implanted osmotic microinfusion pumps, a significnt reduction in trigeminal nerve neoplasia was observed at 90 days of age. This reduction occurred whether the nerve growth factor was given before or after fetal exposure to 20 mg/kg of ethylnitrosourea on day 20 of gestation. These findings support previous reports that nerve growth factor has a protective effect on the developing nervous system against ethylnitrosourea-induced carcinogenesis.
The results differed in several respects with those of a similar experiment from our 1aborat01-y~~ that used Fischer rats inoculated with 50 mg/kg of ethylnitrosourea and injected prenatally or postnatally with concentrated nerve growth factor. The overall rate of trigeminal nerve neoplasia from nerve growth factor-treated and non-nerve growth factor-treated offspring was lower in this experiment than in the previous study. The degree of bilateral involvement of the trigeminal Fig. 3 : Anaplastic neurinoma of tngeminal nerve from 90day-old rat; ethylnitrosourea-exposed, followed by anti-nerve growth factor treatment. HE. nerves was low in all groups of our series whereas in the prior experiment exposure to ethylnitrosourea caused a high incidence of bilateral neoplasms. The most likely explanation for these differences is the much lower dose level of ethylnitrosourea (20 versus 50 mg/ kg) used in the present study. This view is supported by the results of an experiment which indicated that the incidence of ethylnitrosourea-induced neuroectodermal tumors was directly proportional to the dose of the carcinogen.*'
In the initial experiments neonatal nerve growth factor treatment was given on the tenth day after birth or earlier. The best responding group received nerve growth factor during the first five days after birth. In this study nerve growth factor was not received until days 15 to 22 after birth, at which time the nervous system is more developed and may be less dependent on nerve growth factor; therefore, the corresponding reduction in trigeminal nerve neoplasia was not as great.
Previous electron microscopic analysis indicated that poorly differentiated Schwann cells are the most important participants in the formation of ethylnitrosourea-induced anaplastic neurinomas in the trigeminal nerve." Because a reduction in trigeminal nerve early neoplastic proliferation was observed when nerve growth factor was administered both before and after ethylnitrosourea exposure, nerve growth factor must have the capacity to interact not only with the immature Schwann cells but with the transformed Schwann cells as well.
One concept of neoplastic transformation which has gained support with progress in the understanding of gene expression considers neoplastic transformation to be the result of derepression of DNA sequences suppressed in the normal 13-l4 Derepression may play a role in ethylnitrosourea carcinogenesis. l4 Direct biochemical damage to the DNA molecule with a lack of normal repair mechanisms also may play an important role in neoplastic transformation caused by ethylnitrosourea.14 The lack of repair of 06-ethylguanine in the neonatal brain appears to be one explanation for it being a prominent target site for ethylnitrosourea on-c~genesis.~.
Mechanisms operative in embryonal cell differentiation, such as gene suppression, may be responsible for protective effects of the nerve growth factor as well as its ability to alter anaplastic Schwann cells. A number of in vitro experiments support the ability of nerve growth factor to stimulate differentiation of both immature normal and neoplastic cells of neuroectodermal origin. Embryonic chick dorsal root ganglion cells" and normal chromafin cells29 respond to nerve growth factor stimulation by forming neuritic processes. Some neurogenic neoplastic cell lines which undergo differentiation in response to nerve growth factor are the human neuroblastoma line IMR-3225 and the rat pheochromocytoma clone PC 1 2.32 The PC 12 clone has been the most thoroughly tested of the nerve growth factorresponsive cells. Along with neurite outgrowth,' ' devel- A previous study demonstrated that when neonatal rats were treated with anti-nerve growth factor prior to ethylnitrosourea exposure, neural tumors appeared earlier and longevity of the rats was reduced compared to rats given only ethylnitro~ourea.~'*~~ A similar experiment conducted with mice showed that neural tumor 19.21,30,32,33 induction by ethylnitrosourea was enhanced by the reduction of in vivo nerve growth factor levels by antinerve growth factor administration prior to ethylnitrosourea exposure. 36 Our investigation demonstrated no appreciable increase in early neoplastic proliferation when anti-nerve growth factor was administered after ethylnitrosourea exposure. In this study anti-nerve growth factor treatment was not initiated until day 15 postpartum. In the previous studies, anti-nerve growth factor was administered considerably earlier. By day 15, the nervous system may be developed sufficiently to more closely resemble the adult nervous system in which the effect of anti-nerve growth factor is reversible, rather than irreversible as it is in the newborn or fetal nervous system." This could explain the lack of an effect seen following anti-nerve growth factor infusion in this study. These findings following nerve growth factor treatment lend support to the hypothesis that it has a protective effect on the sensitive Schwann cell population in the developing nervous system. Studies in which anti-nerve growth factor would be administered at various stages of gestation and neonatal development are needed to further evaluate its effect on trigeminal nerve early neoplastic proliferation. Experiments also are needed to determine the duration of activity of anti-nerve growth factor when it is stored and delivered via implanted osmotic microinfusion pumps.
It is likely that nerve growth factor is one of many control factors involved in the differentiation of immature cells during embryogenesis. As more is learned about the mechanism for the induction of phenotypic differentiation of target cells by nerve growth factor, its role in experimentally induced and naturally occurring neurooncogenesis will be better understood.
